Collectively, the above considerations suggest that sRAGE might serve as a biomarker in acute MI with respect to prognosis and that maintenance of effective MMP9 activity may serve to stabilize sRAGE production in MI complicated by cardiogenic shock. The gene discussed is MMP9; the disease is myocardial infarction.